Dragan Grabulovski

588 total citations
21 papers, 443 citations indexed

About

Dragan Grabulovski is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Immunology. According to data from OpenAlex, Dragan Grabulovski has authored 21 papers receiving a total of 443 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Radiology, Nuclear Medicine and Imaging, 11 papers in Oncology and 9 papers in Immunology. Recurrent topics in Dragan Grabulovski's work include Monoclonal and Polyclonal Antibodies Research (19 papers), HER2/EGFR in Cancer Research (6 papers) and Peptidase Inhibition and Analysis (4 papers). Dragan Grabulovski is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (19 papers), HER2/EGFR in Cancer Research (6 papers) and Peptidase Inhibition and Analysis (4 papers). Dragan Grabulovski collaborates with scholars based in Switzerland, Sweden and India. Dragan Grabulovski's co-authors include Dario Neri, Julian Bertschinger, Manuela Kaspar, Sarah Batey, Michela Silacci, Hartwig Kosmehl, Luciano Zardi, Roberto Ronca, Alexander Berndt and Richard Woods and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Dragan Grabulovski

19 papers receiving 425 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dragan Grabulovski Switzerland	10	303	235	167	148	39	21	443
Ling C. Santora United States	7	397 1.3×	366 1.6×	182 1.1×	121 0.8×	55 1.4×	10	576
Jochem Gokemeijer United States	9	258 0.9×	275 1.2×	176 1.1×	138 0.9×	20 0.5×	18	460
Patrick Bühler Germany	15	378 1.2×	233 1.0×	211 1.3×	227 1.5×	62 1.6×	21	709
Taichi Kuramochi United States	13	374 1.2×	285 1.2×	231 1.4×	88 0.6×	17 0.4×	23	605
Saskia Meyer Netherlands	11	242 0.8×	169 0.7×	298 1.8×	99 0.7×	12 0.3×	16	454
Jijie Gu United States	9	442 1.5×	359 1.5×	208 1.2×	195 1.3×	39 1.0×	16	591
James Hunt United Kingdom	12	277 0.9×	229 1.0×	317 1.9×	121 0.8×	15 0.4×	17	662
Dmitrij Hristodorov Germany	13	196 0.6×	238 1.0×	225 1.3×	100 0.7×	20 0.5×	21	451
Julia Hambach Germany	8	345 1.1×	281 1.2×	221 1.3×	199 1.3×	57 1.5×	13	611
Hok Seon Kim United States	8	221 0.7×	207 0.9×	204 1.2×	129 0.9×	16 0.4×	11	488

Countries citing papers authored by Dragan Grabulovski

Since Specialization

Citations

This map shows the geographic impact of Dragan Grabulovski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dragan Grabulovski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dragan Grabulovski more than expected).

Fields of papers citing papers by Dragan Grabulovski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dragan Grabulovski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dragan Grabulovski. The network helps show where Dragan Grabulovski may publish in the future.

Co-authorship network of co-authors of Dragan Grabulovski

This figure shows the co-authorship network connecting the top 25 collaborators of Dragan Grabulovski. A scholar is included among the top collaborators of Dragan Grabulovski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dragan Grabulovski. Dragan Grabulovski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Probst, Philipp, et al.. (2025). Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC. Molecular Cancer Therapeutics. 24(6). 803–815. 1 indexed citations

Probst, Philipp, Romain Bertrand, Roger Santimaria, et al.. (2024). Abstract LB124: Targeting NaPi2b with a novel dual TOP1i ADC that shows excellent biophysical properties and high efficacy in vivo. Cancer Research. 84(7_Supplement). LB124–LB124. 1 indexed citations

Probst, Philipp, Romain Bertrand, Roger Santimaria, et al.. (2023). Abstract LB221: Novel peptide linker-based nectin-4 targeting ADC shows improved tolerability with long-lasting anti-tumor efficacy at low doses. Cancer Research. 83(8_Supplement). LB221–LB221. 2 indexed citations

Probst, Philipp, Romain Bertrand, Roger Santimaria, et al.. (2022). Abstract 2910: A CD79b targeting ADC with superior anti-tumor activity and therapeutic index. Cancer Research. 82(12_Supplement). 2910–2910. 1 indexed citations

Schlereth, Bernd, Philipp Probst, Romain Bertrand, et al.. (2022). A CD79b Targeting ADC with Superior Anti-Tumor Activity and Safety Resulting in Significantly Improved Therapeutic Index (TI): Safe and Efficacious CD79b ADC. Blood. 140(Supplement 1). 11568–11569. 1 indexed citations

Probst, Philipp, et al.. (2022). Abstract LB174: Inducing complete and long-lasting tumor eradications at safe and well tolerated doses of a nectin-4 ADC generated with novel peptide linkers for payload conjugation. Cancer Research. 82(12_Supplement). LB174–LB174. 1 indexed citations

Spycher, Philipp René, et al.. (2021). Abstract 1842: CD79b targeting ADC with superior pharmacokinetic profile and anti-tumor activity. Cancer Research. 81(13_Supplement). 1842–1842. 2 indexed citations

Spycher, Philipp René, Dragan Grabulovski, Torsten Hechler, et al.. (2019). Abstract LB-106: Overcoming limitations of current Antibody-Drug Conjugates (ADCs) by a novel linker technology. Cancer Research. 79(13_Supplement). LB–106. 1 indexed citations

Lyman, Michael A., Anjuli M. Timmer, Christine P. Stewart, et al.. (2018). A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases. Journal of Biological Chemistry. 293(24). 9326–9334. 24 indexed citations

10.

Silacci, Michela, Richard Woods, Sarah Batey, et al.. (2015). Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. mAbs. 8(1). 141–149. 77 indexed citations

11.

Klupsch, Kristina, Fabian Buller, Roger Santimaria, et al.. (2015). Bispecific CD3/HER2 Targeting FynomAb Induces Redirected T Cell-Mediated Cytolysis with High Potency and Enhanced Tumor Selectivity. SHILAP Revista de lepidopterología. 4(4). 426–440. 21 indexed citations

12.

Brack, Simon, Babette Schade, Kristina Klupsch, et al.. (2014). A Bispecific HER2-Targeting FynomAb with Superior Antitumor Activity and Novel Mode of Action. Molecular Cancer Therapeutics. 13(8). 2030–2039. 34 indexed citations

13.

Silacci, Michela, et al.. (2014). Linker Length Matters, Fynomer-Fc Fusion with an Optimized Linker Displaying Picomolar IL-17A Inhibition Potency. Journal of Biological Chemistry. 289(20). 14392–14398. 41 indexed citations

14.

Woods, Richard, Simon Brack, Kristina Klupsch, et al.. (2014). Fynomer-antibody fusions targeting HER2 and CD3 for selective killing of HER2 overexpressing tumor cells.. Journal of Clinical Oncology. 32(15_suppl). 3066–3066.

15.

Schlatter, Daniel, Simon Brack, David W. Banner, et al.. (2012). Generation, characterization and structural data of chymase binding proteins based on the human Fyn kinase SH3 domain. mAbs. 4(4). 497–508. 32 indexed citations

16.

Toller, Isabella M., et al.. (2012). Bispecific Fynomer-antibody fusion proteins targeting two epitopes on HER2.. Journal of Clinical Oncology. 30(15_suppl). 2575–2575. 1 indexed citations

17.

Bertschinger, Julian, Dragan Grabulovski, & Dario Neri. (2007). Selection of single domain binding proteins by covalent DNA display. Protein Engineering Design and Selection. 20(2). 57–68. 40 indexed citations

18.

Grabulovski, Dragan & Dario Neri. (2007). Vascular Tumor Targeting. PubMed. 50(4). 491–509. 9 indexed citations

19.

Grabulovski, Dragan, Manuela Kaspar, & Dario Neri. (2006). A Novel, Non-immunogenic Fyn SH3-derived Binding Protein with Tumor Vascular Targeting Properties. Journal of Biological Chemistry. 282(5). 3196–3204. 57 indexed citations

20.

Ronca, Roberto, Manuela Kaspar, Dragan Grabulovski, et al.. (2005). Engineered vascular‐targeting antibody‐interferon‐γ fusion protein for cancer therapy. International Journal of Cancer. 116(2). 304–313. 96 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact